Skip to main content
Subscribe
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Current issue
Archive
Authors
About
Podcasts
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Current issue
Archive
Authors
About
Podcasts
Subscribe
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
tumour necrosis factor inhibitors
Email alerts
tumour necrosis factor inhibitors
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
Casper
Webers
,
Augusta
Ortolan
,
Alexandre
Sepriano
,
Louise
Falzon
,
Xenofon
Baraliakos
,
Robert B M
Landewé
,
Sofia
Ramiro
,
Désirée
van der Heijde
,
Elena
Nikiphorou
Annals of the Rheumatic Diseases
Jan 2023,
82
(1)
130-141;
DOI:
10.1136/ard-2022-223298
Response to: ‘Correspondence on ‘Tapering towards DMARD-free remission in rheumatoid arthritis’ by Garcia
et al
Elise
van Mulligen
,
Pascal Hendrik Pieter
de Jong
Annals of the Rheumatic Diseases
Jan 2023,
82
(1)
e10;
DOI:
10.1136/annrheumdis-2020-219293
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Laura C
Coates
,
Laure
Gossec
,
Elke
Theander
,
Paul
Bergmans
,
Marlies
Neuhold
,
Chetan S
Karyekar
,
May
Shawi
,
Wim
Noël
,
Georg
Schett
,
Iain B
McInnes
Annals of the Rheumatic Diseases
Mar 2022,
81
(3)
359-369;
DOI:
10.1136/annrheumdis-2021-220991
Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
Ingrid Egeland
Christensen
,
Siri
Lillegraven
,
Pawel
Mielnik
,
Gunnstein
Bakland
,
Liz
Loli
,
Joe
Sexton
,
Till
Uhlig
,
Tore K
Kvien
,
Sella A
Provan
Annals of the Rheumatic Diseases
Mar 2022,
81
(3)
398-401;
DOI:
10.1136/annrheumdis-2021-221007
Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables
Alexander
Platzer
,
Farideh
Alasti
,
Josef S
Smolen
,
Daniel
Aletaha
,
Helga
Radner
,
Stephan
Blüml
Annals of the Rheumatic Diseases
Feb 2022,
81
(2)
175-183;
DOI:
10.1136/annrheumdis-2021-220331
Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning
Juergen
Braun
,
Uta
Kiltz
,
Xenofon
Baraliakos
Annals of the Rheumatic Diseases
Jan 2022,
81
(1)
11-14;
DOI:
10.1136/annrheumdis-2021-221406
Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
Imke
Redeker
,
Katinka
Albrecht
,
Joern
Kekow
,
Gerd Rüdiger
Burmester
,
Juergen
Braun
,
Martin
Schäfer
,
Angela
Zink
,
Anja
Strangfeld
Annals of the Rheumatic Diseases
Jan 2022,
81
(1)
41-47;
DOI:
10.1136/annrheumdis-2021-220651
Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy
Muhammad Ruhul Amin
Shipa
,
Raj
Amarnani
,
Su-Ann
Yeoh
,
M D
Mainuddin
,
Michael R
Ehrenstein
Annals of the Rheumatic Diseases
Dec 2021,
80
(12)
1628-1629;
DOI:
10.1136/annrheumdis-2021-220642
What is the optimal target for a T2T approach in axial spondyloarthritis?
Joachim
Sieper
,
Denis
Poddubnyy
Annals of the Rheumatic Diseases
Nov 2021,
80
(11)
1367-1369;
DOI:
10.1136/annrheumdis-2021-220603
Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease
Ming-Han
Chen
,
I-Cheng
Lee
,
Ming-Huang
Chen
,
Ming-Chih
Hou
,
Chang-Youh
Tsai
,
Yi-Hsiang
Huang
Annals of the Rheumatic Diseases
Nov 2021,
80
(11)
1393-1399;
DOI:
10.1136/annrheumdis-2021-220774
Pages
1
2
next ›
last »
CLINICAL
Diagnostics
Clinical diagnostic tests
(1563)
Radiology (diagnostics)
(921)
Surgical diagnostic tests
(505)
Drugs and medicines
Endocrinology
Calcium and bone
(938)
Evidence based practice
Guidelines
(35)
Gastroenterology
Inflammatory bowel disease
(98)
Genetics
(1272)
Immunology (including allergy)
(6648)
Infectious diseases
Bone and joint infections
(93)
Travel medicine
(42)
Neurology
Muscle disease
(198)
Pain (neurology)
(1113)
Nutrition and metabolism
Obesity (nutrition)
(142)
Obstetrics and gynaecology
Menopause (including HRT)
(60)
Ophthalmology
(155)
Orthopaedics
Pathology
Inflammation
(1572)
Pathology
(531)
Pharmacology and therapeutics
Unwanted effects / adverse reactions
(15)
Pharmacology and therapeutics
Radiology
(1357)
Rehabilitation medicine
Disability
(32)
Other rehabilitative therapies
(18)
Physiotherapy
(52)
Renal medicine
(247)
Respiratory medicine
Interstitial lung disease
(181)
Pulmonary hypertension
(39)
Rheumatology
Ankylosing spondylitis
(567)
Biological agents
(731)
Connective tissue disease
(5506)
Degenerative joint disease
(6038)
Drugs: musculoskeletal and joint diseases
(916)
Fibromyalgia
(51)
Musculoskeletal syndromes
(6412)
Osteoarthritis
(1189)
Osteoporosis
(160)
Rheumatoid arthritis
(4213)
Sjogren's syndrome
(6)
Systemic lupus erythematosus
(724)
Vascularitis
(367)
Sports and exercise medicine
Physiotherapy
(33)
NON-CLINICAL
Epidemiology
(1862)
Health economics
(51)
Medical education
Postgraduate
(5)
Occupational and environmental medicine
(32)
Statistics and research methods
Special collections
ARD Lay summaries
(83)
Editor's choice
(161)
Guidelines, Recommendations and Consensus Statements
Open access
(1199)
Press releases
(50)